EUVIMEDEUVIMED entdecken
Fallbericht

Efficacy of Burosumab Every 2 Weeks in an Adult with X-Linked Hypophosphatemia: Should We Learn from Children?

Alessia Marcellino iD, Silvia Bloise, Carmelo Pirone, Giulia Brandino, Pietro Gizzone, Roberta Fraternali, Anna Dilillo, Emanuela Del Giudice, Vanessa Martucci, Mariateresa Sanseviero, Leone Maria Rita, Flavia Ventriglia und 1 weitere

Monoclonal Antibodies in Immunodiagnosis & Immunotherapy · 2023

DOI: 10.1089/mab.2022.0026 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Monoclonal Antibodies in Immunodiagnosis & Immunotherapy, 2023. Verfasst von Alessia Marcellino und 12 weiteren Autor:innen. Beteiligte Einrichtung: Pediatrics and Neonatology Unit, Maternal-Child Department, Santa Maria Goretti Hospital, Sapienza University of Rome, Latina, Italy. Hauptthemen laut MEDLINE: Familial Hypophosphatemic Rickets. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

X-linked hypophosphatemia is a genetic condition that leads to fibroblast-growth-factor 23 (FGF23) increase, causing phosphate renal wasting. Since 2018, burosumab, an anti-FGF23 antibody, has been used for this disease with different dosage in children and adults. We report the case of burosumab administration every 2 weeks, as usually done in children. We retrospectively evaluated parathormone (PTH), alkaline phosphatase, serum phosphate, tubular reabsorption of phosphate (TRP), and 25OH vitamin D every 2 weeks in a 29-year-old man with nephrocalcinosis and tertiary hyperparathyroidism who did not respond to standard treatment with burosumab nor to maximum dosage and was treated with burosumab 90 mg every 2 weeks. His serum phosphate and TRP increased with this regimen compared with 4 weeks frequency (respectively 1.74 ± 0.26 mg/dL vs. 2.3 ± 0.19 mg/dL [ p 0.0004] and 71.3% ± 4.8% vs. 83.9% ± 7.9% [ p 0.01]) with decrease in PTH (183 ± 24.7 pg/mL vs. 109 ± 12.2 pg/mL [ p 0.04]). Burosumab may be a good choice in adult patients with X-linked hypophosphatemia; new data are needed regarding the increase in dosage and/or frequency of administration as usually done in children, to achieve disease control.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Familial Hypophosphatemic RicketsMaleHumansAdultChildInfantAntibodies, MonoclonalRetrospective StudiesPhosphatesAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

burosumabhyperparathyroidismnephrocalcinosisx-linked hypophosphatemia

Substanzen

Antibodies, MonoclonalPhosphatesburosumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Pediatrics and Neonatology Unit, Maternal-Child Department, Santa Maria Goretti Hospital, Sapienza University of Rome, Latina, Italy.
  • Department of Molecular Medicine, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.
  • Department of Emergency Medicine, University of Rome La Sapienza, Roma, Lazio, Italy.

ORCID-Profile: Alessia Marcellino

Zitieren

APA

Marcellino, A., Bloise, S., Pirone, C., Brandino, G., Gizzone, P., Fraternali, R., Dilillo, A., Del Giudice, E., Martucci, V., Sanseviero, M., Rita, L. M., Ventriglia, F., & Lubrano, R. (2023). Efficacy of Burosumab Every 2 Weeks in an Adult with X-Linked Hypophosphatemia: Should We Learn from Children?. Monoclonal Antibodies in Immunodiagnosis & Immunotherapy. https://doi.org/10.1089/mab.2022.0026

Vancouver

Marcellino A, Bloise S, Pirone C, Brandino G, Gizzone P, Fraternali R, et al. Efficacy of Burosumab Every 2 Weeks in an Adult with X-Linked Hypophosphatemia: Should We Learn from Children?. Monoclonal Antibodies in Immunodiagnosis & Immunotherapy. 2023. doi:10.1089/mab.2022.0026

BibTeX
@article{Marcellino2023,
  author = {Marcellino, Alessia and Bloise, Silvia and Pirone, Carmelo and Brandino, Giulia and Gizzone, Pietro and Fraternali, Roberta and Dilillo, Anna and Del Giudice, Emanuela and Martucci, Vanessa and Sanseviero, Mariateresa and Rita, Leone Maria and Ventriglia, Flavia and Lubrano, Riccardo},
  title = {Efficacy of Burosumab Every 2 Weeks in an Adult with X-Linked Hypophosphatemia: Should We Learn from Children?},
  journal = {Monoclonal Antibodies in Immunodiagnosis & Immunotherapy},
  year = {2023},
  doi = {10.1089/mab.2022.0026}
}
Kostenlos starten →